Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideko Yamauchi

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Cancer Science|March 4, 2017
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancerKenji Tamura, Kenichi Inoue, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|May 23, 2022
Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC)Akemi Kataoka, Takayuki Ueno, Hideko Yamauchi, et al.
Breast Cancer (Tokyo, Japan)|March 17, 2023
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patientsMasayuki Nagahashi, YiWei Ling, Chie Toshikawa, et al.
JCO Precision Oncology|June 13, 2020
Actionable gene alterations in an Asian population with triple-negative breast cancerMasayuki Nagahashi, YiWei Ling, Tetsu Hayashida, et al.
Breast Cancer (Tokyo, Japan)|July 13, 2024
High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probandsReiko Yoshida, Tomoko Kaneyasu, Arisa Ueki, et al.
NPJ Breast Cancer|June 23, 2020
Prevalence of disease-causing genes in Japanese patients with <i>BRCA1/2</i>-wildtype hereditary breast and ovarian cancer syndromeTomoko Kaneyasu, Seiichi Mori, Hideko Yamauchi, et al.
Translational Oncology|July 24, 2024
TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohortsShin Takahashi, Nobuaki Sato, Kouji Kaneko, et al.
Future Oncology (London, England)|May 9, 2015
Personalization of loco-regional care for primary breast cancer patients (part 1)Masakazu Toi, Eric P Winer, John R Benson, et al.
Future Oncology (London, England)|May 9, 2015
Personalization of loco-regional care for primary breast cancer patients (part 2)Masakazu Toi, Eric P Winer, John R Benson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerPatricia A Ganz, Hanna Bandos, Tanja Španić, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Cancer Science|March 4, 2017
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancerKenji Tamura, Kenichi Inoue, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|May 23, 2022
Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC)Akemi Kataoka, Takayuki Ueno, Hideko Yamauchi, et al.
Breast Cancer (Tokyo, Japan)|March 17, 2023
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patientsMasayuki Nagahashi, YiWei Ling, Chie Toshikawa, et al.
JCO Precision Oncology|June 13, 2020
Actionable gene alterations in an Asian population with triple-negative breast cancerMasayuki Nagahashi, YiWei Ling, Tetsu Hayashida, et al.
Breast Cancer (Tokyo, Japan)|July 13, 2024
High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probandsReiko Yoshida, Tomoko Kaneyasu, Arisa Ueki, et al.
NPJ Breast Cancer|June 23, 2020
Prevalence of disease-causing genes in Japanese patients with <i>BRCA1/2</i>-wildtype hereditary breast and ovarian cancer syndromeTomoko Kaneyasu, Seiichi Mori, Hideko Yamauchi, et al.
Translational Oncology|July 24, 2024
TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohortsShin Takahashi, Nobuaki Sato, Kouji Kaneko, et al.
Future Oncology (London, England)|May 9, 2015
Personalization of loco-regional care for primary breast cancer patients (part 1)Masakazu Toi, Eric P Winer, John R Benson, et al.
Future Oncology (London, England)|May 9, 2015
Personalization of loco-regional care for primary breast cancer patients (part 2)Masakazu Toi, Eric P Winer, John R Benson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast CancerPatricia A Ganz, Hanna Bandos, Tanja Španić, et al.
Pageof 13